

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, 08 July, 2021

ORDER

S. O. 2742(E):-In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Telmisartan + Nebivolol Tablet	Each uncoated Bilayered Tablet Contains: Telmisartan IP 40 mg Nebivolol Hydrochloride IP Equivalent to Nebivolol 5 mg	1 Tablet	M/s Eris Lifesciences Limited	13.61
2.	Glimeperide + Pioglitazone + Metformin HCL (SR) Tablet	Each uncoated bilayered tablet contains: Glimeperide IP 2mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (in sustained release form)	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Eris Lifesciences Limited	12.85
3.	Glimeperide + Pioglitazone + Metformin HCL (SR) Tablet	Each uncoated bilayered tablet contains: Glimeperide IP 1mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (in sustained release form)	1 Tablet	M/s Windlas Biotech Pvt. Ltd. / M/s Eris Lifesciences Limited	8.73
4.	Glimeperide + Metformin HCL (SR) Tablet	Each uncoated tablet contains: Glimeperide IP 2mg Metformin Hydrochloride IP 1000mg (in sustained release form)	1 Tablet	M/s M/s Agron Remedies Private Limited / M/s Cadila Pharmaceuticals Ltd.	9.44
5.	Glimeperide + Metformin HCL (SR) Tablet	Each uncoated tablet contains: Glimeperide IP 1mg Metformin Hydrochloride IP 1000mg (in sustained release form)	1 Tablet	M/s M/s Agron Remedies Private Limited / M/s Cadila Pharmaceuticals Ltd.	6.86
6.	Dextromethorphan Hydrobromide + Chlorpheniramine Meleate Syrup	Each 5ml contains: Dextromethorphan Hydrobromide IP 10mg Chlorpheniramine Meleate IP 2mg	1 ML	M/s East African (India) Overseas / M/s Cadila Pharmaceuticals Ltd.	0.64
7.	Esomeprazole & Domperidone sustained release capsule	Each hard gelatine capsule contains: Esomeprazole Magnesium IP eq. to Esomeprazole 40mg (as enteric coated pellets), Domperidone IP 30mg (as sustained release pellets)	1 Capsule	M/s Skymap Pharmaceuticals Pvt. Ltd. / M/s Jagsonpal Pharmaceuticals Ltd.	10.20
8.	Telmisartan + Amlodipine + Hydrochlorothiazide Tablet	Each film coated tablet contains: Telmisartan IP 40mg, Amlodipine Besylate IP eq. to Amlodipine 5mg	1 Tablet	M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cadila Pharmaceuticals Ltd.	9.56

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
		Hydrochlorothiazide IP 12.50 mg			
9.	Nebivolol Hydrochloride + Telmisartan Tablet	Each uncoated bilayered tablet contains: Nebivolol Hydrochloride IP eq. to Nebivolol 5mg Telmisartan IP 40mg	1 Tablet	M/s Windlas Biotech limited / M/s Eris Lifesciences Limited	13.61
10.	Vitamin D3 Oral Drops	Each ml contains: Cholecalciferol (Vitamin D3) IP 800IU	1 ML	M/s Akums Drugs & Pharmaceuticals Limited / M/s Cipla Limited	5.06
11.	Paracetamol + Methocarbamol + Diclofenac Potassium tablet	Each Film coated tablet contains: Paracetamol IP 325mg Methocarbamol IP 500mg Diclofenac Potassium BP 50mg tablet	1 Tablet	M/s Shiv Industries / M/s Profic Organic Limited	7.96

Note:

- The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
- In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/221/89/2021/F

F. No. 8(89)/2021/D.P./NPPA-Div.-II

(Prasenjit Das)
Deputy Director